See more : Geron Corporation (GERN) Income Statement Analysis – Financial Results
Complete financial analysis of PharmaBlock Sciences (Nanjing), Inc. (300725.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaBlock Sciences (Nanjing), Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Electric Royalties Ltd. (ELECF) Income Statement Analysis – Financial Results
- Resbud SE (RES.WA) Income Statement Analysis – Financial Results
- Premier American Uranium Inc. (PUR.V) Income Statement Analysis – Financial Results
- GB Group plc (GBGPF) Income Statement Analysis – Financial Results
- Lionco Pharmaceutical Group Co.,Ltd. (603669.SS) Income Statement Analysis – Financial Results
PharmaBlock Sciences (Nanjing), Inc. (300725.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.pharmablock.com
About PharmaBlock Sciences (Nanjing), Inc.
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial production. It primarily businesses include building blocks collection, supplying from discovery, development to commercial; building blocks driven libraries for drug discovery; development and manufacturing of RSMs, intermediates, APIs, and drug products for drug development and commercial. The company was founded in 2006 and is based in Nanjing, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.73B | 1.59B | 1.20B | 1.02B | 662.23M | 478.25M | 273.25M | 188.38M | 136.13M | 76.64M | 58.55M |
| Cost of Revenue | 991.67M | 869.50M | 623.34M | 554.17M | 320.57M | 201.74M | 103.51M | 63.37M | 52.91M | 25.49M | 17.61M |
| Gross Profit | 733.53M | 725.20M | 578.29M | 468.06M | 341.66M | 276.51M | 169.74M | 125.01M | 83.22M | 51.15M | 40.94M |
| Gross Profit Ratio | 42.52% | 45.48% | 48.13% | 45.79% | 51.59% | 57.82% | 62.12% | 66.36% | 61.13% | 66.75% | 69.92% |
| Research & Development | 169.17M | 168.32M | 114.02M | 90.93M | 69.22M | 44.35M | 24.73M | 16.31M | 8.99M | 7.45M | 6.96M |
| General & Administrative | 65.02M | 71.93M | 66.56M | 66.99M | 25.58M | 16.46M | 14.37M | 28.39M | 28.41M | 3.90M | 2.45M |
| Selling & Marketing | 53.21M | 40.96M | 24.28M | 30.66M | 24.25M | 20.68M | 17.64M | 11.72M | 4.47M | 2.61M | 1.95M |
| SG&A | 118.22M | 112.89M | 90.84M | 97.65M | 49.83M | 37.14M | 32.02M | 40.10M | 32.87M | 6.51M | 4.40M |
| Other Expenses | 261.54M | 147.48M | 92.07M | 60.55M | 55.74M | 11.43M | 2.94M | 3.94M | 2.76M | 1.82M | 1.03M |
| Operating Expenses | 522.60M | 428.70M | 296.93M | 249.12M | 174.80M | 132.31M | 88.91M | 84.02M | 60.72M | 25.81M | 20.00M |
| Cost & Expenses | 1.54B | 1.30B | 920.28M | 803.29M | 495.37M | 334.06M | 192.42M | 147.39M | 113.63M | 51.29M | 37.61M |
| Interest Income | 13.44M | 14.06M | 11.27M | 4.05M | 2.27M | 972.71K | 284.74K | 113.79K | 160.61K | 291.85K | 83.32K |
| Interest Expense | 68.20M | 45.72M | 9.18M | 630.52K | 3.26M | 1.00M | 61.00K | 225.66K | 9.70K | 352.71K | 448.57K |
| Depreciation & Amortization | 116.09M | 94.47M | 58.82M | 26.19M | 22.49M | 18.17M | 13.45M | 8.55M | 4.24M | 3.50M | 3.11M |
| EBITDA | 403.56M | 471.53M | 581.73M | 229.61M | 196.73M | 180.96M | 89.44M | 53.43M | 26.53M | 30.21M | 25.15M |
| EBITDA Ratio | 23.39% | 29.23% | 48.42% | 23.16% | 30.49% | 37.13% | 33.65% | 30.51% | 23.03% | 40.59% | 42.41% |
| Operating Income | 184.60M | 296.71M | 492.96M | 194.13M | 163.54M | 142.98M | 74.12M | 40.77M | 24.14M | 24.65M | 20.56M |
| Operating Income Ratio | 10.70% | 18.61% | 41.02% | 18.99% | 24.69% | 29.90% | 27.13% | 21.64% | 17.73% | 32.16% | 35.11% |
| Total Other Income/Expenses | 36.78M | 26.56M | 14.81M | 10.38M | 8.82M | 11.43M | 2.94M | 3.88M | 2.76M | 1.71M | 1.03M |
| Income Before Tax | 221.38M | 323.26M | 507.77M | 204.50M | 172.35M | 154.41M | 77.06M | 44.65M | 26.90M | 26.35M | 21.58M |
| Income Before Tax Ratio | 12.83% | 20.27% | 42.26% | 20.01% | 26.03% | 32.29% | 28.20% | 23.70% | 19.76% | 34.39% | 36.86% |
| Income Tax Expense | 24.01M | -2.63M | 4.00M | 20.30M | 20.28M | 19.91M | 9.27M | 9.61M | 7.04M | 3.90M | 3.34M |
| Net Income | 197.36M | 314.22M | 486.56M | 184.21M | 152.07M | 133.36M | 67.18M | 36.12M | 19.93M | 22.47M | 18.25M |
| Net Income Ratio | 11.44% | 19.70% | 40.49% | 18.02% | 22.96% | 27.89% | 24.59% | 19.17% | 14.64% | 29.32% | 31.17% |
| EPS | 0.99 | 1.57 | 2.45 | 0.99 | 0.82 | 0.72 | 0.47 | 0.27 | 0.18 | 0.53 | 0.17 |
| EPS Diluted | 0.98 | 1.57 | 2.44 | 0.75 | 0.82 | 0.72 | 0.47 | 0.27 | 0.18 | 0.53 | 0.17 |
| Weighted Avg Shares Out | 199.35M | 199.66M | 198.99M | 186.60M | 185.90M | 185.90M | 143.70M | 132.68M | 109.83M | 109.86M | 109.86M |
| Weighted Avg Shares Out (Dil) | 201.39M | 200.14M | 199.41M | 244.36M | 185.90M | 186.42M | 143.71M | 132.68M | 109.86M | 109.86M | 109.86M |
Source: https://incomestatements.info
Category: Stock Reports